About 93 results

ALLMedicine™ Acute Erythroid Leukemia Center

Research & Reviews  36 results

Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, ...
Blood Cancer Journal; Reichard KK, Tefferi A et. al.

Nov 4th, 2022 - Pure erythroid leukemia (PEL), also known as acute erythroid leukemia (AEL), is recognized as a distinct morphologic entity by both the 2016 and 2022 World Health Organization (WHO) classification system. By contrast, the 2022 International Consen...

AML-144 Uroporphyrinogen Decarboxylase (UROD) Is a Therapeutically Targetable Dependenc...
Clinical Lymphoma, Myeloma & Leukemia; Friske J, Fukuda Y et. al.

Sep 28th, 2022 - Acute erythroid leukemia (AEL) is a disease of erythroid lineage that commonly exhibits TP53 mutations, a complex karyotype, and poor prognosis irrespective of currently available therapies. To identify AEL dependencies and novel therapeutic targe...

Erythroleukemia: an Update.
Current Oncology Reports; Weinberg OK, Arber DA

Apr 21st, 2021 - Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset...

Modeling acute erythroid leukemia via CRISPR.
Blood Zhang JP, Cheng T

Mar 26th, 2021 - Modeling acute erythroid leukemia via CRISPR.|2021|Zhang JP,Cheng T,|

Modeling and targeting of erythroleukemia by hematopoietic genome editing.
Blood Iacobucci I, Qu C et. al.

Jan 30th, 2021 - Acute erythroid leukemia (AEL) is characterized by a distinct morphology, mutational spectrum, lack of preclinical models, and poor prognosis. Here, using multiplexed genome editing of mouse hematopoietic stem and progenitor cells and transplant a...

see more →

Clinicaltrials.gov  1 results

Molecular Characterization of Acute Erythroid Leukemia (M6-AML) Using Targeted Next-generation Sequencing

Aug 10th, 2016 - Acute erythroid leukemia (AEL) is a morphologically distinct, infrequent (o5%) acute myeloid leukemia (AML) designed as M6 in the French- American-British (FAB) classification. The World Health Organization classification recognizes two subclasses...

see more →